Mark Campbell is the Chief Operating Officer at EmVenio Research, a PCM Trials Company. He joined PCM Trials during its acquisition of EmVenio in February 2025, having initially joined EmVenio in May 2021. With over 25 years of leadership experience in drug development, research site networks, and clinical technology, he brings valuable expertise to both EmVenio and PCM Trials. Prior to joining EmVenio, Mark worked with notable global drug developers Johnson & Johnson and Amgen, as well as global leaders in site networks Synexus Clinical Research and PPD’s Accelerated Enrollment Division.